Updated Version of the COVID-19 Treatment Guidelines Now Available

The COVID-19 Treatment Guidelines Panel (the Panel) is pleased to announce the release of a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

This new version of the Guidelines includes the following updates:

• To reflect the results of large randomized controlled trials that enrolled hospitalized patients, certain recommendations in Chloroquine or Hydroxychloroquine With or Without Azithromycin have been updated to differentiate between hospitalized and nonhospitalized patients. 
• Preliminary, unpublished data from randomized controlled trials have not demonstrated the efficacy of sarilumab or tocilizumab in patients with COVID-19. The data on the efficacy of siltuximab in patients with COVID-19 are limited and come from unpublished studies. In Interleukin-6 Inhibitors, the Panel’s recommendation on using interleukin-6 inhibitors for the treatment of COVID-19 has been revised accordingly.
• A new subsection titled Ivermectin was added to Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19 to address the use of ivermectin for the treatment of COVID-19. 
• The new Special Considerations in Adults and Children with Cancer section provides recommendations for screening certain asymptomatic cancer patients for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The Panel also emphasizes the importance of consulting a hematologist or oncologist before adjusting a patient’s cancer-directed therapy. Decisions about administering cancer-directed therapies to patients with SARS-CoV-2 infection should be made on a case-by-case basis; clinicians should consider the indication for chemotherapy, the goals of care, and the patient’s history of tolerance to the treatment. 
• Table 2a has been removed from the guidelines. The summaries of the clinical data for each antiviral agent are now included in new subsections that can be found under the individual drug sections.   
• Special Considerations in Pregnancy has been updated to include the most recent epidemiological data for COVID-19 in pregnant people in the United States. This section also provides additional guidance on maternal and fetal monitoring in hospitalized patients who are pregnant and who have received a diagnosis of COVID-19. 
• Other sections have been updated to include new data from clinical trials and observational cohort studies.

For a complete list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.